Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
- PMID: 28474673
- PMCID: PMC5424158
- DOI: 10.1038/ncomms15081
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Abstract
Single-cell transcriptome profiling of tumour tissue isolates allows the characterization of heterogeneous tumour cells along with neighbouring stromal and immune cells. Here we adopt this powerful approach to breast cancer and analyse 515 cells from 11 patients. Inferred copy number variations from the single-cell RNA-seq data separate carcinoma cells from non-cancer cells. At a single-cell resolution, carcinoma cells display common signatures within the tumour as well as intratumoral heterogeneity regarding breast cancer subtype and crucial cancer-related pathways. Most of the non-cancer cells are immune cells, with three distinct clusters of T lymphocytes, B lymphocytes and macrophages. T lymphocytes and macrophages both display immunosuppressive characteristics: T cells with a regulatory or an exhausted phenotype and macrophages with an M2 phenotype. These results illustrate that the breast cancer transcriptome has a wide range of intratumoral heterogeneity, which is shaped by the tumour cells and immune cells in the surrounding microenvironment.
Conflict of interest statement
The authors declare no competing financial interests.
Figures







Similar articles
-
Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.Hum Pathol. 2013 Oct;44(10):2055-63. doi: 10.1016/j.humpath.2013.03.010. Epub 2013 May 21. Hum Pathol. 2013. PMID: 23701942 Free PMC article.
-
Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC.Cancer Immunol Immunother. 2021 Jan;70(1):189-202. doi: 10.1007/s00262-020-02669-7. Epub 2020 Jul 17. Cancer Immunol Immunother. 2021. PMID: 32681241 Free PMC article.
-
ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.Int J Cancer. 2021 Jul 1;149(1):200-213. doi: 10.1002/ijc.33539. Epub 2021 Mar 18. Int J Cancer. 2021. PMID: 33634878
-
Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.Eur J Surg Oncol. 2017 Apr;43(4):642-648. doi: 10.1016/j.ejso.2016.10.025. Epub 2016 Nov 17. Eur J Surg Oncol. 2017. PMID: 27889196 Review.
-
The Immunology of Hormone Receptor Positive Breast Cancer.Front Immunol. 2021 May 11;12:674192. doi: 10.3389/fimmu.2021.674192. eCollection 2021. Front Immunol. 2021. PMID: 34135901 Free PMC article. Review.
Cited by
-
Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade.Cancer Immunol Res. 2021 Jul;9(7):765-778. doi: 10.1158/2326-6066.CIR-20-0499. Epub 2021 Apr 10. Cancer Immunol Res. 2021. PMID: 33839688 Free PMC article.
-
Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer.J Pers Med. 2021 Feb 19;11(2):149. doi: 10.3390/jpm11020149. J Pers Med. 2021. PMID: 33669749 Free PMC article. Review.
-
Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors.Adv Sci (Weinh). 2024 Oct;11(38):e2309755. doi: 10.1002/advs.202309755. Epub 2024 Aug 13. Adv Sci (Weinh). 2024. PMID: 39136172 Free PMC article.
-
Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.Horm Cancer. 2020 Aug;11(3-4):129-147. doi: 10.1007/s12672-020-00388-0. Epub 2020 Jun 26. Horm Cancer. 2020. PMID: 32592004 Free PMC article. Review.
-
Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer.Front Oncol. 2021 Mar 17;10:626912. doi: 10.3389/fonc.2020.626912. eCollection 2020. Front Oncol. 2021. PMID: 33816214 Free PMC article.
References
-
- Harvey J. M., Clark G. M., Osborne C. K. & Allred D. C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474–1481 (1999). - PubMed
-
- Cardoso F. et al.. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729–735 (2008). - PubMed
-
- Sparano J. A. & Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26, 721–728 (2008). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous